Liverpool Neuro-Oncology Group Expands Clinical Training With Locum Fellowship Opening
The University of Liverpool Clinical Academic neuro-oncology group is seeking a Locum Clinical Fellow in Neurosurgical Oncology, a post that sits inside a research-heavy service built around both operative practice and academic output. The listing places the role in Liverpool and describes it as a full-time, contract appointment with a salary starting from £76,582 a year. The posting date is 16 October 2026, and applications close on 30 October 2026.
This is not a routine service position. The fellowship is embedded in a team that combines clinical training with an active research portfolio spanning meningioma, metastases, and glioma. In practical terms, that means the fellow would be entering an environment where brain tumor care is paired with study design, data collection, and the kind of translational work that can influence how neurosurgical oncology evolves over time.
A Research Group Built Around Surgical Brain Tumor Disease
The Liverpool group is described as comprising one professor, one senior lecturer, three ACFs, and three PhD staff. That staffing mix signals a deliberately academic structure rather than a purely service-led unit. Clinical fellows working in that setting are typically exposed to the full arc of neuro-oncology care: operative planning, postoperative decision-making, multidisciplinary coordination, and research activity that runs alongside daily clinical demands.
The disease areas named in the post are clinically distinct, even when they share the same anatomical territory. Meningioma can range from indolent incidental lesions to tumors that create pressure symptoms or recur after treatment. Metastases often require fast-moving decisions because the underlying systemic cancer may be active elsewhere. Glioma carries its own biologic complexity, with infiltrative growth that limits the surgical margin and makes postoperative management especially challenging. A fellowship tied to all three tumor types suggests broad exposure rather than narrow subspecialization.
One sentence captures the clinical weight of the post: neurosurgical oncology is where millimeters shape outcomes.
Trials Sit at the Center of the Fellowship Environment
The group’s research profile extends beyond descriptive case series. It leads several multicenter neurosurgery randomized controlled trials: ROAM, STOP EM, and RESTART. Even without additional protocol details in the listing, the presence of three named randomized trials indicates a mature research culture with experience in recruitment, coordination, and clinical governance across sites.
Randomized trials in neurosurgery are demanding because the field sits at the intersection of urgent decision-making, anatomical precision, and variable patient trajectories. Surgical interventions are difficult to standardize, perioperative care can vary between centers, and tumor biology often complicates interpretation of results. A team that can carry multicenter randomized work alongside basic and translational imaging and laboratory research is operating at a level that depends on both scientific discipline and logistical coordination.
The fellowship therefore appears designed for a doctor who wants more than case volume. It is a position for someone who wants exposure to the mechanisms that generate evidence: patient selection, tissue handling, imaging interpretation, and the construction of datasets that can answer questions too large for a single ward or operating list.
Translational Work Adds Biological Depth to the Clinical Role
The posting also points to basic and translational imaging and laboratory work. In neuro-oncology, that combination matters because tumor behavior is rarely explained by the scan alone. Imaging can define extent, edema, mass effect, and postoperative change, while laboratory research helps probe why some tumors recur, resist treatment, or behave unpredictably despite apparently similar appearances.
That dual track is especially relevant in meningioma, metastases, and glioma, where radiologic appearance and tissue biology do not always line up neatly. A lesion that looks stable can still harbor biologic aggression. A surgically accessible tumor can still pose long-term risk if the underlying disease process continues to advance after resection. The academic setting described here seems built to keep those tensions in view rather than treating surgery as an isolated technical act.
In a neuro-oncology fellowship, the academic side is not ornamental. It shapes how clinicians frame prognosis, monitor recurrence, and think about the limits of surgery alone.
What the Posting Reveals About Training and Service Priorities
The structure of the Liverpool group suggests a service that values continuity between research fellows, doctoral scientists, and senior academic clinicians. That can be important for a locum clinical fellow, who often needs rapid integration into a team while also contributing to ongoing studies. The arrangement implies an environment where clinical care and research are not separate tracks but overlapping responsibilities.
For the right candidate, that overlap may be the main attraction. A locum post can still provide a concentrated period of exposure to complex cranial tumor work, while also allowing participation in a portfolio that already includes multicenter randomization and translational science. The listing does not describe specific procedural duties, case mix proportions, or on-call expectations, so any deeper inference would go beyond the text. What can be said directly is that the role sits inside a group with enough academic infrastructure to support substantive research alongside frontline neurosurgical oncology.
Why This Kind of Post Matters in Neuro-Oncology
Training posts like this help maintain the pipeline for subspecialists who can move between theatre, clinic, and research governance without losing sight of the patient at the center of each decision. Brain tumor care often requires that balance. The surgeon must weigh operative risk against neurologic function, anticipated recurrence, postoperative pathology, and the likelihood that adjuvant therapy will still be needed after resection.
A fellow working within a group active in meningioma, metastases, and glioma research gains repeated exposure to those trade-offs. The educational value lies not just in seeing more cases, but in seeing how academic neurosurgery turns bedside questions into studies, and studies back into practice. The Liverpool listing shows a team with the personnel and trial portfolio to support that cycle.
Applications close on 30 October 2026, leaving a short window for candidates interested in a full-time contract role within a highly academic neurosurgical oncology setting. The post offers access to a group already engaged in multicenter randomized trials and translational work, but it does not spell out how the fellowship will divide clinical service from research time, which remains the most practical question for any applicant weighing the role.